Nippon Kayaku Co (4272) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
19 Aug, 2025Executive summary
Net sales for FY 2025 1H rose 11.4% year-over-year to ¥109.1 billion, with strong Mobility & Imaging and Fine Chemicals performance, while Life Science sales remained flat.
Operating income surged 134.1% year-over-year to ¥11.2 billion, with all business units showing profit growth.
Profit attributable to owners of parent declined slightly to ¥6.0 billion, mainly due to a ¥2.6 billion valuation loss on investment securities.
Overseas sales ratio increased, reflecting strong international performance.
Ordinary income increased 40.3% year-over-year to ¥11.7 billion.
Financial highlights
Gross profit margin improved to 31.9% from 29.3% year-over-year, with gross profit rising to ¥34.8 billion.
Operating income margin doubled to 10.2% from 4.9% year-over-year.
ROE rose to 5.7%, up 4.1 percentage points from the previous year.
Equity ratio remains high at 73.8%.
Cash and deposits decreased by ¥12.4 billion, while inventories and property, plant, and equipment increased.
Outlook and guidance
Full-year FY 2025 forecasts project net sales of ¥220.3 billion and operating income of ¥19.3 billion, both up year-over-year.
Profit attributable to owners of parent is forecast at ¥15.3 billion, up 271.9% year-over-year.
Dividend forecast maintained at ¥45.00 per share for the full year.
All business units expected to see higher sales and profits, with new product launches and expanded sales in key markets.
Latest events from Nippon Kayaku Co
- Profit attributable to owners of parent rose 30.1% on 4.0% sales growth, outlook steady.4272
Q3 20262 Feb 2026 - Net sales up 4.1% and profit nearly doubled on investment gains despite cost pressures.4272
Q2 202612 Nov 2025 - Strong sales and profit growth driven by Mobility & Imaging and Fine Chemicals; outlook revised up.4272
Q1 202519 Aug 2025 - Sharp profit growth and raised forecasts driven by Mobility & Imaging and Fine Chemicals.4272
Q3 202519 Aug 2025 - Record profit and strong segment growth; FY 2026 sees sales up, profit slightly down.4272
Q4 202519 Aug 2025 - Sales rose but profits fell amid higher costs and global risks; outlook remains cautious.4272
Q1 202619 Aug 2025